17 Progesterone for preterm birth prevention: a potential $2 billion opportunity

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 3, 2007, Pages 194-195

  Armstrong, Joanne ^a  

^a AETNA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE;

CEREBRAL PALSY; COST BENEFIT ANALYSIS; EDITORIAL; GESTATIONAL AGE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEARING IMPAIRMENT; HOSPITAL CARE; HOSPITAL COST; HUMAN; INFANT MORTALITY; MENTAL DEFICIENCY; MORBIDITY; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; UNITED STATES; VISUAL DISORDER;

COSTS AND COST ANALYSIS; FEMALE; HUMANS; HYDROXYPROGESTERONES; PREGNANCY; PREMATURE BIRTH;

EID: 33847618755     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.12.022     Document Type: Editorial

References (16)

1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmayer S. Births: final data for 2004. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr55/nvsr55_01.pdf. Accessed on Oct. 2, 2006.
2. Callahan W.M., MacDorman M.F., Rasmussen S.A., Qin C., and Lackritz E.M. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 118 (2006) 1566-1573
3. Hack M., Flannery D.J., Schluchter M., Cartar L., Borawski E., and Klein N. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 346 (2002) 149-157
4. Marlow N., Wolke D., Bracewell M.A., and Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 352 (2005) 9-19
5. Wang M.L., Dorer D.J., Fleming M.P., and Catlin E.A. Clinical outcomes of near-term infants. Pediatrics 114 (2004) 372-376
6. In: Behrman R.E., and Butler A.S. (Eds). Institute of Medicine. Preterm birth: causes, consequences, and prevention (2006), National Academy Press, Washington (DC)
7. Peristats. March of Dimes Birth Defects Foundation, 2003. Available at: http://www.marchofdimes.com/peristats/prematurity.aspx?reg=99. Accessed on Oct. 6, 2005.
8. Gilbert W.M., Nesbitt T.S., and Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol 102 (2003) 488-492
9. Schmitt S.K., Sneed L., and Phibbs C.S. Costs of newborn care in California: a population-based study. Pediatrics 117 (2006) 154-160
10. Phibbs C.S., and Schmitt S.K. Estimates of the cost and length of stay for changes that can be attributed to one week increases in gestation al age for premature infants. Early Hum Dev 82 (2006) 85-95
11. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003) 2379-2385
12. St. John E.B., Nelson K.G., Cliver S.P., Bishnoi R.R., and Goldenberg R.L. Cost of neonatal care according to gestational age at birth and survival status. Am J Obstet Gynecol 182 (2000) 170-175
13. US Food and Drug Administration (FDA), Division of Reproductive and Urologic Products. 17 alpha hydroxyprogesterone caproate for prevention of preterm birth: overview of FDA background document. Available at: http://www.fda.gov/ohrms/dockets/AC/06/briefing/2006-4227B1-02-01-FDA-Ba ckground.pdf. Accessed on Oct. 5, 2006.
14. Sanchez-Ramos L., Kaunitz A.M., and Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 105 (2005) 273-279
15. Ness A., Dias T., Damus K., Burd I., and Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 195 (2006) 1174-1179
16. Caritis S., Rouse D., and NICHD MFMU. A randomized controlled trial of 17-hydroxyprogesterone caproate (17-OHPC) for the prevention of preterm birth in twins. Am J Obstet Gynecol 195 (2006) S2